217 related articles for article (PubMed ID: 35378914)
1. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for
Gan Y; Ren J; Xian J; Yu H; Jin J; Li D; Li W
Int J Gen Med; 2022; 15():3405-3416. PubMed ID: 35378914
[TBL] [Abstract][Full Text] [Related]
2. Albumin-to-alkaline phosphatase ratio at diagnosis predicts survival in patients with metastatic non-small-cell lung cancer.
Li D; Yu H; Li W
Onco Targets Ther; 2019; 12():5241-5249. PubMed ID: 31303770
[No Abstract] [Full Text] [Related]
3. Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer.
Zhou S; Jiang W; Wang H; Wei N; Yu Q
Cancer Med; 2020 Sep; 9(17):6268-6280. PubMed ID: 32691996
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non-small cell lung cancer after surgery.
Zhang L; Zhang H; Yue D; Wei W; Chen Y; Zhao X; Zhu J; Zhang B; Zhang Z; Wang C
Thorac Cancer; 2019 Jul; 10(7):1581-1589. PubMed ID: 31161711
[TBL] [Abstract][Full Text] [Related]
5. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
6. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
7. Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies.
Cai X; Chen Z; Chen J; Ma X; Bai M; Wang T; Chen X; Wu D; Wei L; Li X; Lin Q; Wen J; Ruan D; Lin Z; Dong M; Wu X
J Cancer; 2018; 9(1):189-197. PubMed ID: 29290785
[No Abstract] [Full Text] [Related]
8. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Extensive-Disease Small-Cell Lung Cancer: A Retrospective Cohort Study.
Zhou S; Wang H; Jiang W; Yu Q; Zeng A
Cancer Manag Res; 2020; 12():2015-2024. PubMed ID: 32256109
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
[No Abstract] [Full Text] [Related]
11. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy.
Chen ZH; Zhang XP; Cai XR; Xie SD; Liu MM; Lin JX; Ma XK; Chen J; Lin Q; Dong M; Wu XY; Wen JY; Xu RH
J Cancer; 2018; 9(19):3467-3478. PubMed ID: 30310503
[No Abstract] [Full Text] [Related]
12. Prognostic impact of the pretreatment albumin to alkaline phosphatase ratio for nonmetastatic breast cancer patients.
Long ZQ; Hua X; Zhang WW; Lv SW; Deng JP; Guo L; He ZY; Lin HX
Cancer Manag Res; 2019; 11():4809-4814. PubMed ID: 31213902
[No Abstract] [Full Text] [Related]
13. Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients.
Sandfeld-Paulsen B; Aggerholm-Pedersen N; Winther-Larsen A
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885242
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
15. Albumin-to-alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation-negative advanced non-small cell lung cancer.
Liu X; Li Y; Zhao Q; Jiang H; Ni J; Cai H
Clin Respir J; 2021 May; 15(5):540-549. PubMed ID: 33565707
[TBL] [Abstract][Full Text] [Related]
16. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
[TBL] [Abstract][Full Text] [Related]
17. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer.
Li YT; Zhou XS; Han XM; Tian J; Qin Y; Zhang T; Liu JL
World J Gastrointest Oncol; 2022 May; 14(5):1002-1013. PubMed ID: 35646278
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Significance Of Pretreatment Albumin/alkaline Phosphatase Ratio In Patients With Stage IB-IIA Cervical Cancer.
Zhang C; Li Y; Ji R; Zhang W; Zhang C; Dan Y; Qian H; He A
Onco Targets Ther; 2019; 12():9559-9568. PubMed ID: 32009792
[TBL] [Abstract][Full Text] [Related]
20. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
